Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Pilot Study of Buspirone for the Treatment of Anxiety in Youth with Autism Spectrum Disorders
NCT03432065 · Massachusetts General Hospital · PHASE2 · withdrawn · last registry update 2024-09-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was withdrawn due to competing research interests and slow recruitment.” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-09-18Results posted on the registry: Spaulding Rehabilitation Hospital, Buspirone + Placebo (NCT05041322)
- 2025-09-04Phase 3 first posted: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Experimental regimen + Control regimen (NCT07153406)
- 2025-08-28Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Brexpiprazole + Placebo (NCT04174365)
- 2025-06-13Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Brexpiprazole + Sertraline (NCT04124614)
- 2025-05-30Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Brexpiprazole + Sertraline (NCT04174170)
- 2025-05-23Results posted on the registry: University of Massachusetts, Worcester, Brexpiprazole (NCT03526354)
- 2025-04-11Results posted on the registry: University of California, San Diego, amisulpride + bromocriptine (NCT04128683)
- 2025-02-25Results posted on the registry: Massachusetts General Hospital, Buspirone (NCT01850355)
- 2025-01-29Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., 3-6mg QLM1016 + 10-20 mg Aripiprazole oral solution film (NCT06799559)
- 2025-01-20Also stopped (withdrawn): Children's Hospital of Fudan University, Drug Aripiprazole (NCT05361993)
- 2025-01-16Results posted on the registry: Brain and Cognition Discovery Foundation, Vortioxetine + Placebo (NCT05047952)
- 2024-11-20Phase 3 first posted: Shanghai Changzheng Hospital, Carvedilol and alverine (NCT06696248)
- 2024-11-14Results posted on the registry: Otsuka Pharmaceutical Co., Ltd., Brexpiprazole + Placebo (NCT03620981)
- 2024-10-21Results posted on the registry: Technical University of Munich, Olanzapine or amisulpride (NCT01029769)
- 2024-10-03Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Brexpiprazole (NCT04186403)
- 2024-09-19Results posted on the registry: Massachusetts General Hospital, Buspirone (NCT04807517)
- 2024-09-19Results posted on the registry: All India Institute of Medical Sciences, Bhubaneswar, Amisulpride + Olanzapine-Fluoxetine Combination (NCT04876521)
- 2024-09-19Results posted on the registry: Otsuka Pharmaceutical Co., Ltd., Brexpiprazole (NCT03724942)
- 2024-09-19Phase 3 first posted: Chengdu Kanghong Pharmaceutical Group Co., Ltd., Hydrochloride Carliprazine capsules + Aripiprazole tablets (NCT06589817)
- 2024-09-19Results posted on the registry: University of Texas Southwestern Medical Center, Aripiprazole + Placebo (NCT02918370)
- 2024-09-19Results posted on the registry: Elizabeth Berry-Kravis, 5-Hydroxytryptophan + Ergoloid Mesylates (NCT05030129)
- 2024-09-05Phase 3 first posted: Benaroya Research Institute, Amisulpride IV Prevention + Amisulpride IV Treatment (NCT06585540)
- 2024-08-20Phase 3 first posted: Future University in Egypt, Vortioxetine 20Mg Tab (NCT06561438)
- 2024-08-09Results posted on the registry: Otsuka Pharmaceutical Co., Ltd., Brexpiprazole + Placebo (NCT03697603)
- 2024-08-05Results posted on the registry: Otsuka Pharmaceutical Co., Ltd., 2mg conventional tablet, once-weekly tablets (NCT04118127)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision